key: cord-0684939-5vjh79c6
authors: Caohuy, Hung; Eidelman, Ofer; Chen, Tinghua; Yang, Qingfeng; Bera, Alakesh; Walton, Nathan; Pollard, Harvey B.
title: Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration into human lung cells
date: 2021-06-02
journal: bioRxiv
DOI: 10.1101/2021.06.02.446343
sha: d79b15ace1f911aa32e1a3209fef135ab4f807f5
doc_id: 684939
cord_uid: 5vjh79c6

To initiate SARS-CoV-2 infection, the Receptor Binding Domain (RBD) on the viral spike protein must first bind to the host receptor ACE2 protein on pulmonary and other ACE2-expressing cells. We hypothesized that cardiac glycoside drugs might block the binding reaction between ACE2 and the Spike (S) protein, and thus block viral penetration into target cells. To test this hypothesis we developed a biochemical assay for ACE2:Spike binding, and tested cardiac glycosides as inhibitors of binding. Here we report that ouabain, digitoxin, and digoxin are high-affinity competitive inhibitors of ACE2 binding to the Wuhan S1 and the European [E614G] S1 proteins. These drugs also inhibit ACE2 binding to the Wuhan RBD, as well as to RBD proteins containing the S. Africa [E484K], Mink [Y453F] and UK [N501Y] mutations. As hypothesized, we also found that ouabain and digitoxin blocked penetration by SARS-CoV-2 Spike-pseudotyped virus into human lung cells. These data indicate that cardiac glycosides may block viral penetration into the target cell by first inhibiting ACE2:Spike binding. Clinical concentrations of ouabain and digitoxin are relatively safe for short term use for subjects with normal hearts. It has therefore not escaped our attention that these common cardiac medications could be deployed worldwide as inexpensive repurposed drugs for anti-COVID-19 therapy.

COVID-19 is a pandemic pneumonia-like disease, caused by the SARS-CoV-2 virus, that was first detected late in 2019 in Wuhan, China [1] [2] [3] . The virus initially gains access to type II pneumocytes in the lung when the Receptor Binding Domain (RBD) on the viral Spike (S) protein binds to the extracellular carboxypeptidase domain of the ACE2 receptor protein on the cell surface [4] [5] [6] . The native spike structure is composed of three identical protomers. Each protomer is divided into two domains: the distal N-terminal S1 spike "tip", containing the RBD, and the residual C-terminal S2, transmembrane fusion protein. In the intact Spike, the binding process appears to depend on the RBD of at least one protomer transitioning from a down "closed" state to an upper "open" state 7, 8 . In the down "closed" state the RBD has been shown by Cryo-EM to be partially hidden by glycosylated spike amino acids 9 . When activated by ACE2, the RBD domain emerges towards the spike tip, from the hidden state, into the "open" state. Thus from the perspective of ACE2, there may be at least two accessible conformations of the RBD: either a lower, mostly hidden structure, or a raised, much less hidden structure 7 . However, how ACE2 induces the transition of the RBD from a closed state to the open state is presently not yet understood.

Following binding of ACE2 to the Spike RBD, the Spike protein is cleaved by Furin, a host protease, into the distal S1 segment, and the residual S2 segment 10, 11 . Furin cleavage reveals the C-terminal CendR domain, to which the host protein neuropilin 1 binds and promotes cell entry 10 . The residual S2 domain is further sequentially optimized for membrane fusion by the host proteases TMPRSS2 and endosomal CTSL 6, 9 . However, since the Wuhan viral strain was first sequenced, the virus has mutated into more infectious and possibly more lethal strains. Examples of such mutations in the spike include the European mutation at residue 614, [D614G] 12, 13 . This mutation appears to increase spike density and flexibility 14, 15 . The mutation also creates an additional cleavage site for serine elastase 2 (neutrophil elastase) that promotes further exposure and priming of S2 6 lineage. Since infection depends on successful viral entry into the cell, this complex entry mechanism has therefore become a promising target for anti-viral SARS-CoV-2 drug discovery.

In an effort to jumpstart COVID-19 drug discovery, unbiased in vitro and in silico screens of FDA-approved and other drugs have been performed to find possible high affinity blockers of SARS-CoV-2 infectivity [19] [20] [21] . In some of these screens the common cardiac medications digitoxin, digoxin and ouabain, have emerged as top contenders. Experimentally, time-of addition experiments with infection by native SARS-CoV-2 of green monkey kidney Vero cells have been interpreted to suggest that ouabain blocks virus penetration, while digoxin blocks infectivity at an unknown intracellular site 22 . Experiments with digoxin 23 and digitoxin 24 have also been interpreted as blocking entry of native MERS-CoV into target cells. Consistently, in silico docking sites for digitoxin have been identified in the RBD 25 . However, other in silico studies have shown that cardiac glycoside drugs might also interact with the active site of the viral main protease, Mpro 26 . Thus it remains to be determined where in the infectivity process these cardiac glycoside drugs act, since in most studies the experimental endpoints have been viral progeny counts.

Based on the foregoing we hypothesized that cardiac glycoside drugs such as ouabain, digitoxin and digoxin might block the binding reaction between ACE2 and the viral Spike (S) protein, and thus block viral penetration into target cells (Supplemental Figure S1 ). To test this hypothesis we first developed a biochemical method to measure the kinetics of ACE2 binding to immobilized variants of the Spike S1 and RBD domains. We found that binding occurred by a positively cooperative mechanism. Next we tested the cardiac glycoside drugs for their ability to block the ACE2:Spike binding reaction. These drugs were all found to be competitive inhibitors.

Lastly we tested whether cardiac glycoside drugs could block viral entry into human lung cells with SARS-CoV-2-spike-pseudotyped virus. The most potent blocker was ouabain, followed by digitoxin. The least potent was digoxin. These cardiac glycoside drugs are inexpensive, widely available, and clinically safe for subjects with normal hearts [27] [28] [29] . It is therefore possible that these drugs could be repurposed for COVID-19 prevention and therapy.

ACE2 binds with positive cooperativity to Receptor Binding Domain proteins.

The substrate-binding plots in Figure 1a show that both the original Wuhan RBD protein, and the larger original Wuhan [D614] S1 domain protein, appear to have very similar binding isotherms at 37 o C. However, the mutant European [D614G] S1 differs quantitatively from the original Wuhan S1 and Wuhan RBD. Furthermore, inspection of the substrate-binding plots show 5 that a lag in binding occurs at low concentrations of ACE2. Thus, the binding isotherms appear to show a distinct sigmoid appearance in the low concentration range that is independent of mutation. To further test this possibility, we constructed Eadie-Hofstee (EH) plots for each of the domains. In the case of the original Wuhan [D614] S1 protein Figure 1b shows a "concave-down" structure at the lower values of ACE2 binding. Such behavior is characteristic of positive cooperativity, including positive cooperativity by monomeric proteins or enzymes 30 . Figure 1c and Figure 1d show the same descriptive positive cooperativity behavior in Eadie-Hofstee plots for both the mutant [D614G] S1 protein and the Wuhan RBD protein, respectively. Hill plots of these data also show the modest but significant elevations in the Hill coefficient, (nH) which is typical of monomeric systems 30 (Supplementary Figure S5) . It is apparent that since both Spike S1 proteins contain the same upstream RBD domain, the occurrence of either the amino acid aspartic acid (D) or glycine (G) at residue 614 has the ability to modify ACE2 affinity for the common RBD. The data further indicate that the positive cooperativity property may be intrinsic to the ACE2 interaction with the RBD. The values of KD for each variant are included in Table 1 .

We also tested ACE2 binding properties to RBD proteins containing three other diseaseassociated mutations, and compared them to the original Wuhan RBD. Figure 2a shows the substrate-binding isotherms for the Mink [Y453F] RBD and the UK [N501Y] RBD proteins, and compares them with the Wuhan S1, and the Wuhan RBD proteins. Figure 2b shows the Eadie-Hoffstee plots for the Wuhan S1 and the Wuhan RBD. The Wuhan RBD domain is contained within the Wuhan S1 protein, and as expected the data are virtually superimposable. Both curves are concave down at low ACE2 binding levels, and thus are consistent with the interpretation of positive cooperativity. Figures 2c and 2d show the same type of data for the Mink [Y453F] RBD protein and the UK [N501Y] RBD protein, respectively. The Eadie-Hoffstee plots are concave down at low values of binding, while the slopes in the linear parts of the plots are substantially reduced compared to the Wuhan S1 proteins. As summarized in Table 1 , KD values for the Mink and UK variants are significantly reduced from 72 to 30 and 25 ng/ml ACE2, respectively. Thus mutations in the RBD in the region interacting with ACE2 can affect the KD for the interaction. Figure 3b to emphasize this comparison with other variant RBD proteins. To further test for the ACE2 positive cooperativity mechanism we analyzed the S.Africa [E484K] RBD data 6 using an Eadie-Hoffstee plot (Figure 3c) . As for the other RBD variants the S.Africa [E484K] RBD protein has a profound "concave-down" structure for the lower values of ACE2 binding. The

Bmax is similar to that of the other variants, but the binding constant, KD, trends higher ( Table 1) .

The Hill plot for the S.Africa [E484K] RBD protein is shown in Figure 3d . The slope for the S.Africa [E484K] variant, (nH), is 1.25 ± 0.05, and is significantly higher than for the other RBD proteins (Supplementary Figure S5) . The elevated Hill constant is consistent with the relatively exaggerated concavity of the EH plot at low levels of ACE2 binding. Thus both the cooperativity and the affinity of ACE2 for the receptor binding domain can be modified by mutations not only in the RBD domain itself, but also by mutations elsewhere in the S1 region of the spike protein.

Sigmoid substrate-binding plots can also be due to autocatalysis, such as can occur during phase transitions. Therefore, to test for whether ACE2 binding to the Spike S1 derivatives might be due to autocatalysis as opposed to positive cooperativity, per se, we analyzed the ACE2 To test for the ability of cardiac glycosides to inhibit ACE2 binding to the RBD protein, we measured ACE2 binding to the RBD protein in the presence of digitoxin, digoxin and ouabain (Figure 4a) . Reduced ACE2 binding in the presence of these drugs is evident. The substratebinding isotherms also indicate that the sigmoid appearance is sustained. Thus the positively cooperative binding mechanism is still present. The DBB plots also provide evidence for a sustained positive cooperativity mechanism for ACE2:RBD binding in the presence of the cardiac glycoside drugs (see Supplemental Figure S3 ).

In addition, the Eadie-Hoffstee plots for all three drugs show that the cardiac glycosides differentially increase the KD values while keeping the Bmax values approximately constant (see for the European mutant [D614G] S1 protein ( Figure 6 ). These data are consistent with a competitive inhibition mechanism. The individual EH plots show that these drugs all appear to lower the affinity for ACE2 by 50-100% while keeping the Bmax approximately constant. These kinetic data are summarized in Table 2 , and indicate that of the three drugs tested ouabain is the most potent inhibitor, followed by digitoxin and digoxin.

Digitoxin and digoxin have three sugars on their 3'-OH groups, while the more potent inhibitor ouabain has only one sugar (see Supplemental Figure S1b ). We therefore tested whether the sugar moieties on digitoxin or digoxin contributed to inhibitory activity. Digitoxingenin and digoxigenin are the sugar-free analogues of digitoxin and digoxin, respectively. We found that for ACE2 binding to the Wuhan S1 spike protein, 30 nM digitoxigenin was approximately as inhibitory as digitoxin (Supplemental Figure S4a) . A similar result was noted for digoxin and digoxigenin (Supplemental Figure S4b) . We also found similar results for inhibition of ACE2 Figure   7a shows the Substrate-Binding plots for ACE2 binding to the S.Africa [E484K] RBD protein. The inhibitory effects are clearly apparent for the cardiac glycoside drugs ouabain, digitoxin and digoxin, and the two sugar-free derivatives, digitoxigenin and digoxigenin. The sigmoid character of the ACE2 binding isotherm is also evident, and is more clearly shown in Figure 7b for the low ACE2 concentrations. Figure 7c shows the Eadie-Hoffstee plots for both drugs and derivatives.

All are concave-down at low concentrations of ACE2. Thus the apparent positive cooperativity for ACE2 binding is preserved in the presence of all three cardiac glycosides and the two sugarfree derivatives. Furthermore, all of these drugs and their sugar-free derivatives have inhibitory activity, although the most active drug is ouabain. Finally, the Bmax values for these drugs are similar while the slopes of the linear portion of the EH plots at high ACE2 concentration are systematically higher than the control. Thus the inhibitory mechanisms appear classically competitive. Figure Cardiac glycosides block penetration of Spike-pseudotyped VSV virus into lung cells.

To test whether cardiac glycosides blocked the viral penetration process we tested drug effects on cell entry by luciferase (luc)-loaded Spike-pseudotyped VSV(S) viral particles. To further focus the experiment on the earliest entry steps we also used a triple tandem time-ofaddition method. Briefly, VSV(S) particles were first preincubated for one hour with cardiac glycoside drugs in DMEM at 37 o C. Secondly, the particles and drugs were then preincubated with the A549 cells for two hours at 37 o C. Thirdly, the viral particles and drugs were washed away and replaced by complete DMEM medium. The A549 cells were then incubated for 24 hours at 37 o C before assay for luciferase. Figure 8a shows the results of luminescence backgroundcorrected activity of luc-loaded pseudotyped VSV(S) over the active ranges for digitoxin, digoxin and ouabain. Ouabain was found to potently suppress viral entry. Digitoxin was less potent and digoxin was the least potent. Based on these data the Hill plot-based EC-50 value for ouabain was calculated to be 16 ± 1 nM (N=3, ± SE). The positive and negative control values are given in Supplemental Table S1 . The inhibition data are similar when measured either by ratio to the luminescence control (Figure 8b) , or by % of positive control (Figure 8c) . As a negative control, and to test for whether human ACE2 receptor was required for cell penetration, mouse 3T3 cells were substituted for human A549 cells. Mouse 3T3 cells were found to be inactive (Figure 8d) .

Finally, as a positive human control, post convalescent serum from an unidentified, recovered COVID-19 patient was found to inhibit penetration of the SARS-CoV-2 spike pseudotyped VSV(S) in a dose-dependent manner (Supplemental Figure S8 ). Since the SARS-CoV-2 spike pseudotyped VSV(S) only reports on viral penetration, and is not infectious, the data indicate that ouabain most potently blocks viral penetration into human lung cells, likely at a very early stage of the entry process.

For the SARS-CoV-2 virus to infect a target cell, the Receptor Binding Domain on the viral Spike protein must bind to the receptor protein ACE2 on the cell surface. However, fully understanding the factors controlling this binding process is only at an early stage. Here we have tested the hypothesis that cardiac glycoside drugs such as ouabain, digitoxin, and digoxin might block the binding reaction between ACE2 and the Spike (S) protein, and thus block viral penetration into human lung cells. In this paper both parts of this hypothesis have been experimentally validated in three overlapping tests. Firstly, we found that ACE2 binding to various spike variants occurred by a positively cooperative mechanism. Not unexpectedly, we also found that mutations in the RBD, specifically Mink [Y453F] and UK [N501Y], significantly increased ACE2 binding affinity, while the S.Africa [E484K] mutation trended towards reduction in ACE2 binding affinity. We also validated a previous finding that the [D614G] mutation, on a part of the spike S1 protein outside of the RBD, also reduced ACE2 binding affinity to the RBD. Thus the effect of a mutation that enhances infectivity need not necessarily increase the affinity of ACE2 for the RBD. In addition, as hypothesized we found that ouabain, digitoxin and digoxin were also high-affinity competitive inhibitors of ACE2:Spike binding. In addition, we found that the relative inhibitory potencies of these drugs, as defined by the Ki, were mutation-and drug-dependent.

Lastly, we found that ouabain and digitoxin, but not digoxin, potently blocked SARS-CoV-2 Spike pseudotyped virus penetration into human lung cells. Inasmuch these drugs are widely available, and are clinically safe for those with normal hearts 29 , it is quite possible that these common cardiac medications could be repurposed for anti-COVID-19 therapy.

In retrospect the positively cooperative mechanism by which ACE2 binds to the spike might have been anticipated. For example it has been recently reported that when either the RBD protein or the intact spike protein binds to ACE2 there is a 3-10-fold increase in the intrinsic ACE2 carboxypeptidase activity 32 . Thus functional changes in ACE2 can be induced by interaction with spike proteins. Furthermore, structural analysis by Cryo-EM shows that the binding of RBD to ACE2 induces a ~12° movement of the ACE2 C-terminal domain toward the N-terminal domain, and also induces an opening of the ACE2 substrate binding pocket 33 . Such changes in conformation are intrinsic to the two major models for positive cooperativity, the "induced fit" model 30, 34, 35 and the earlier "sequential" or "symmetry" model 30, 36 . Furthermore, the modest Hill coefficients shown here for ACE2:Spike interactions are also consistent with enzymatic and biophysical data previously reported for positively cooperative monomeric systems such as glucokinase 37 and trypsin-like proteases 38 . These data therefore might be consistent with an "induced fit" hypothesis, in which ACE2 could initially bind to the RBD with low affinity, and then undergo further conformational changes to accomplish a higher affinity interaction. On the other hand, dimers of native ACE2 have been shown to be preferred as a binding partner for the RBD for a pseudotyped SARS-CoV-2 spike 33 . Thus monomers of ACE2 bind poorly to intact viral Spikes, compared to the binding by ACE2 dimers. In addition, it has been reported that more than one RBD in a triple protomer spike can elevate into the open state and bind to multiple host ACE2 extracellular domains 39, 40 . Finally, recent in silico modeling has suggested that higher concentrations of recombinant extracellular ACE2 might trend towards a dimeric polymerization state 41 . We conclude that further analysis will be necessary to distinguish whether one or both models might best describe the experimental data.

Based on data shown here, we have also shown that other regions in the Spike complex might have conformational effects on the RBD and thus its affinity for ACE2. The [D614G] mutation in the S1 protein may be an example of how changes at some distance from the RBD sequence can raise the KD for ACE2 binding to the RBD. How this happens, and why there are possible advantages to the virus for infectivity, are insights yet to be discovered. However, it has been reported that the [D614G] mutation increases spike flexibility, and spike density by 4-5 fold 14, 15 . Thus in exchange for a reduction in the affinity for ACE2, other properties that enhance infectivity may have been acquired. Nonetheless, the inhibition constants for the cardiac glycosides were not significantly affected by the [D614G] mutation.

The anti-viral properties of cardiac glycosides have been well documented, not only for some RNA viruses such as coronaviruses but for some DNA viruses as well 42 . In the case of RNA viruses, ouabain and digoxin have been reported to block native MERS-CoV entry into green monkey kidney Vero cells 23 . Digitoxin has also been reported to have the same effect on MERS-CoV entry into Vero cells 24 . Recent time-of-addition studies on native SARS-CoV-2 with Vero cells have also been interpreted to indicate that ouabain may block viral entry, with an EC50 of 24 nM 22 . However, digoxin, with an EC50 value of 43 nM, did not appear to block viral entry, and has been hypothesized to interfere with infection at some intracellular site 22 . Consistently, the analysis reported here directly shows that ouabain and digitoxin, but less so digoxin, act as blockers of viral entry into human lung cells. In sharp contrast, the effects of ouabain and other cardiac glycosides on other RNA and DNA viruses have not been associated with viral entry.

Rather the effects have been generally on downstream activities associated with virus propagation and infection 42 . Thus the specific anti-viral activity of blocking viral entry into cells by low concentrations of ouabain, and to a lesser extent by digitoxin, appears to be limited to the coronaviruses, and here specifically to SARS-CoV-2. Therefore we suggest that the high affinity and mutation-dependent specificity of the ACE2:RBD binding reaction may point to a biologically important process that might be used to therapeutic advantage for COVID-19.

Cardiac glycosides such as digitoxin have a recent history as potent inhibitors of the TNF-dependent proinflammatory host response to influenza virus infection, also known as cytokine storm 43 . Consistently, digitoxin has also been reported to be a potent and efficacious suppressor of TNF-dependent proinflammatory cytokine expression in cystic fibrosis cells and patients as well 28, 44 . Digitoxin also inhibits tumor growth and NFB signaling in a pre-clinical rat model of castration resistant prostate cancer 45 . Recently, digitoxin was reported to be among the top ten inhibitors of TNF-activated NFB signaling in a screen of 2,800 FDA approved drugs 46 . The mechanism for digitoxin inhibition of TNF signaling to NFB is due to blocking the interaction between the proinflammatory TNF/TNFR1 complex and the TNF Associated Death Domain (TRADD) protein 47 . TRADD is the first intracellular adaptor for the activated TNF/TNFR1 complex. Mutant CFTR also fails to suppress TRADD expression, thus explaining why cystic fibrosis patients present with chronic TNF-dependent proinflammatory disease in lung and other organs 48 . By contrast, digitoxigenin and digoxigenin, the sugar-free analogues of digitoxin and digoxin, respectively, are relatively inactive as blockers of the TNF-dependent host response 49 But whether RBD conformation intrinsically changes in response to ACE2 binding is a study for the future. An additional limitation of our study is that we have utilized a luc-loaded, SARS-CoV-2 pseudotyped virus as a test for biological activity rather than a native SARS-CoV-2 virus.

However, it was only with a viral particle model that we could unambiguously demonstrate that cardiac glycosides inhibited viral entry. As mentioned above, ouabain itself has also been previously demonstrated to block infectivity by native SARS-CoV-2 virus, albeit in a green monkey Vero cell 22 .

Clinical concentrations of cardiac glycosides are relatively safe for subjects with normal hearts, and it is therefore possible that these drugs could be repurposed for COVID-19 therapy.

Digitoxin, digoxin, ouabain, digitoxigenin and digoxigenin were purchased from Sigma- When cardiac glycosides were to be added, they were dissolved in Reagent Diluent (0.5% BSA in PBST), added in 100 L volumes to each well, and incubated at 37 o C overnight. The next day, plates were inverted gently on paper towels for 5 minutes. A volume of 100L dilutions of ACE2

were added to each well, supplemented with cardiac glycosides as appropriate, and incubated at Tables   Table 1 . Binding constants KD for ACE2 binding to spike variants. Figure S2 . Spike S1 Variants Only a. Figure S8 . Patient-positive-convalescent serum control using SARS-COV-2 pseudovirus assay. Recovered COVID-19 patient serum sample was diluted in DMEM and treated as described in methods by the triple tandem time-of-addition method. No cardiac glycosides were added. Control data are summarized in Supplemental Table 1 . Table 1 .

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A Novel Coronavirus from Patients with Pneumonia in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein

Neuropilin-1 is a host factor for SARS-CoV-2 infection

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate

Structural impact on SARS-CoV-2 spike protein by D614G substitution

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Fast-spreading U.K. virus variant raises alarms

Recurrent mutations in SARS-CoV-2 genomes isolated from mink point to rapid host-adaptation. bioRxiv

Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19

ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells

Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. bioRxiv

in silico screening of potential spike glycoprotein inhibitors of SARS-CoV-2 with drug repurposing strategy

Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations

Ouabain pharmacokinetics in dog and man. Determination by radioimmunoassay

Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding

Digitalis and Allied Cardiac Glycosides Goodman and Gilman's The Pharmacological Basis of Therapeutics Eighth Edition

Understanding allosteric and cooperative interactions in enzymes

Can we distinguish positive cooperativity from autocatalysis in enzyme kinetics

High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity

Structural basis of receptor recognition by SARS-CoV-2

Comparison of experimental binding data and theoretical models in proteins containing subunits

Cooperativity and the methods of plotting binding and steady-state kinetic data

On the nature of allosteric transitions: A plausible model

Dual allosteric activation mechanisms in monomeric human glucokinase

Allostery in trypsin-like proteases suggests new therapeutic strategies

Cell entry mechanisms of SARS-CoV-2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

ACE2 homo-dimerization, human genomic variants and interaction of host proteins explains high population specific differences in outcomes of COVID-19. bioRxiv

The Antiviral Effects of Na,K-ATPase Inhibition: A Minireview

Classical Drug Digitoxin Inhibits Influenza Cytokine Storm, With Implications for Covid-19 Therapy

Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients

Digitoxin Inhibits Epithelial-to-Mesenchymal-Transition in Hereditary Castration Resistant Prostate Cancer

Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action

Cardiac glycosides inhibit TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor

CFTR Controls the Activity of NF-kappaB by Enhancing the Degradation of TRADD. Cellular physiology and biochemistry 40

Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells

Studies on digitalis. X. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients in heart failure

The effect of digoxin on exercise capacity and exercising cardiac function in cystic fibrosis

Absorption of digoxin in children with cystic fibrosis

Efect of digoxin on the circulation in normal man

Hemodynamic effects of cardiac glycosides on normal human subjects during rest and exercise

A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells

Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay

Supplementary Figures and Tables Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration into human lung cells

Uniformed Services University of the Health Sciences

Consortium for Health and Military Performance (CHAMP)

Uniformed Services University of the Health Sciences

We gratefully acknowledge support for this project by the Cooperative Health Initiative Research Program (CHIRP), supported by NHLBI/NIH (IAA-AA-HL-14-007; H.B. Pollard, PI); and by the Consortium for Health and Military Performance (CHAMP), supported by Warfighter Readiness: Optimizing Human Performance (HU00011920047; MEM-91-10314; P. Deuster, PI). We thank Laiman Tavedi for expert technical and administrative support. We thank Bette S. Pollard for her prediction that cardiac glycosides might block the interaction between ACE2 and SARS-CoV-2 spike protein, thereby preventing virus propagation, infection and COVID-19, and thank her for critically reading the manuscript.The opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army, Department of Defense, the U.S. Government or the Uniformed Services University of the Health Sciences. The use of trade names does not constitute an official endorsement or approval of the use of such reagents or commercial hardware or software. This document may not be cited for purposes of advertisement.Contributions: HP, OE, TC, HC, and QY designed experiments. HC, TC, QY performed experiments. OE, AB, NW, HC and HP contributed to data analysis. HP, HC and OE wrote the paper. All co-authors critically read the paper.

The authors declare no competing interests associated with this manuscript.